Skip to main content
Livermore
Livermore
ZHEN

Morgan Stanley

SEC CIK
0000895421
Latest filing
Aug 13, 2026

ALGS holding history

Aligos Therapeutics, Inc. in every 13F filed by Morgan Stanley, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

ALGS overviewAll 13F holders of ALGSFull Q2 2026 holdings

Shares (Q2 2026)
204
Value
$1.18K
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of ALGS by Morgan Stanley, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026204$1.18K<0.1%−14−6.4%ReducedHolders
Q1 2026218$1.62K<0.1%−2,302−91.3%ReducedHolders
Q4 20252,520$23.5K<0.1%−8,764−77.7%ReducedHolders
Q3 202511,284$110.6K<0.1%+7,279+181.7%AddedHolders
Q2 20254,005$28.9K<0.1%−3,493−46.6%ReducedHolders
Q1 20257,498$61.9K<0.1%+4,265+131.9%AddedHolders
Q4 20243,233$128.8K<0.1%+3,099+2,312.7%AddedHolders
Q3 2024134$1.16K<0.1%+2+1.5%AddedConverted for a 1-for-25 splitHolders
Q2 20243,300$1.16K<0.1%00.0%UnchangedHolders
Q1 20243,300$3.23K<0.1%+1,300+65.0%AddedHolders
Q4 20232,000$1.33K<0.1%00.0%UnchangedHolders
Q3 20232,000$1.49K<0.1%−1,000−33.3%ReducedHolders
Q2 20233,000$2.91K<0.1%−129,724−97.7%ReducedHolders
Q1 2023132,724$116.0K<0.1%+130,371+5,540.6%AddedHolders
Q4 20222,353$2.24K<0.1%−7,929−77.1%ReducedHolders
Q3 202210,282$11.0K<0.1%−42,331−80.5%ReducedHolders
Q2 202252,613$64.0K<0.1%−27,497−34.3%ReducedHolders
Q1 202280,110$171.0K<0.1%+28,440+55.0%AddedHolders
Q4 202151,670$613.0K<0.1%−417,734−89.0%ReducedHolders
Q3 2021469,404$7.28M<0.1%+453,545+2,859.9%AddedHolders
Q2 202115,859$324.0K<0.1%−18,456−53.8%ReducedHolders
Q1 202134,315$780.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.